论文部分内容阅读
目的:对比培美曲塞与多西他赛联合顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法:将48例NSCLC患者随机分为观察组(n=25)和对照组(n=23)。观察组给予培美曲塞联合顺铂治疗,对照组给予多西他赛联合顺铂治疗,21d为1个周期,2个周期后评价疗效,每个周期进行1次毒副作用评价。结果:观察组与对照组客观有效率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)分别为36.0%(9/25)和30.4%(7/23)、84.0%(21/25)和84.0%(18/23)、9.3和8.9个月,两组比较差异无统计学意义,χ2值分别为0.167、0.159和1.576,P值分别为0.683、0.611和0.209。但观察组中性粒细胞减少及脱发的发生率显著低于对照组,分别为28.0%和56.5%、28.0%和60.9%,差异有统计学意义,χ2值分别为4.009和5.259,P值分别为0.045和0.022。结论:培美曲塞联合顺铂与多西他赛联合顺铂的近期疗效相当,但前者毒副作用较后者轻,提高了化疗耐受性,适合临床进一步推广应用。
Objective: To compare the short-term curative effect and side effects of pemetrexed combined with docetaxel plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Forty-eight NSCLC patients were randomly divided into observation group (n = 25) and control group (n = 23). The observation group received pemetrexed combined with cisplatin, the control group received docetaxel combined with cisplatin, 21 days for one cycle, two cycles after the evaluation of efficacy, toxicity evaluation once per cycle. Results: The objective effective rate (ORR), disease control rate (DCR) and progression - free survival (PFS) of the observation group and the control group were 36.0% (9/25) and 30.4% (7/23) and 84.0% / 25), 84.0% (18/23), 9.3 and 8.9 months respectively. There was no significant difference between the two groups (χ2 = 0.167,0.159 and 1.576, P = 0.683,0.611 and 0.209, respectively). However, the incidences of neutropenia and alopecia in the observation group were significantly lower than those in the control group (28.0% and 56.5%, 28.0% and 60.9%, respectively), the values of χ2 were 4.009 and 5.259, respectively 0.045 and 0.022. CONCLUSION: Pemetrexed combined with cisplatin and docetaxel combined with cisplatin has similar curative effect in the short term, but the former has less toxic and side effects than the latter, which improves the chemotherapy tolerance and is suitable for further clinical application.